Back to search
Schistosoma Hematobium Infection
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Schistosoma Hematobium Infection trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Schistosoma Hematobium Infection trials you may qualify forThis study aims to develop and evaluate a nanobody-based urine diagnostic test for Schistosoma haematobium infection through IPSE antigen detection. Approximate…
Objectives:To reduce the risk of S. haematobium pathology recurrences during the three years following vaccine administration and to control the safety of this…
Previous clinical trials have already demonstrated the safety of the candidate vaccine in adults as well as in children, in good health or infected with schisto…
Schistosomiasis is one of most important human parasitic diseases worldwide. Pregnant women and their infants are two vulnerable population groups, particularly…
Open labelled, non randomized study to evaluate the effects of Artemisinin based Combined Therapies(ACTs) on schistosomiasis since Praziquantel (PZQ) which is p…
The purpose of this study is to determine what causes some people to become sick, and others not, when they are infected with the parasite Schistosoma haematobi…
Clinical Trial Phase:Phase III Primary Objectives: * Compare Mirazid and Praziquantel cure rates for both Schistosoma species. * Compare Mirazid and Praziquan…
The purpose of this study is to evaluate the clinical performance of the one-step Fyodor Urine Malaria Test (UMT), to determine its accuracy (sensitivity and sp…
The aim of this study is to investigate the change in iron metabolism in relation to malaria and helminth infections using a stable isotope technique.
SchistoVAN aims to study the role of schistosomiasis infection in the modulation of the immune response of children to childhood vaccine antigens, as well as th…
To assess the influence of seasonal variations in Schistosoma haematobium transmission on treatment outcome (morbidity and re-infection)